People living with HIV who are taking single-tablet regimens have better medication adherence and lower hospitalizations than those taking multi-tablet regimens, explained Ian Frank, MD, professor of medicine, Perelman School of Medicine, University of Pennsylvania,
People living with HIV who are taking single-tablet regimens have better medication adherence and lower hospitalizations than those taking multi-tablet regimens, explained Ian Frank, MD, professor of medicine, Perelman School of Medicine, University of Pennsylvania,
Transcript
How have once-a-day single-tablet regimens impacted patient outcomes compared with multi-tablet regimens?
I’m a believer in simplicity, and I love single-tablet regimens, and I love them for several reasons. If people are only on their HIV medication, taking 1 pill a day is the easiest and simplest kind of regimen that we can offer an individual. But also, by putting all the medications in 1 pill, we can’t have a mix up by the pharmacy. Pharmacies can’t prescribe some of the regimens in a combination but not others because they’re not available in stock. We can’t have individuals adhering to some of the medications but not all of the medications in a regimen. We can’t have confusions on the part of the patient in terms of remembering to take medications or forgetting to take other medications.
So, with the goal of trying to promote adherence, single-tablet regimens have been, in my opinion, a major advance. And, there are studies that show that individuals who are on single-tablet regimens, they have better adherence and less hospitalization than individuals who are on a multiple-tablet regimen that contain the exact same components as in the single-tablet regimen.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen